Product Description
AZD-7687 is a potent inhibitor of Diacylglycerol O-acyltransferase 1 (DGAT1) which was developed by AstraZeneca for the treatment obesity and type 2 diabetes mellitus. (Sourced from: https://drugs.ncats.io/drug/6QTJ9P2NYT)
Mechanisms of Action: DGAT Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Type 2 Diabetes|Overweight|Obesity|Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| JSMAD | P1 |
Completed |
Obesity|Type 2 Diabetes |
2011-07-01 |
|
| D2710C00002 | P1 |
Completed |
Overweight |
2011-03-01 |
|
| D2710C00001 | P1 |
Completed |
Healthy Volunteers |
2010-06-01 |